Introduction
============

Among 278 million suffering from deafness worldwide, half are induced by hereditary factors, with 200 to 300 genes having been identified ([@b1-mmr-16-06-7915]). Based on the presence of other symptoms, hearing impairment may be divided into syndromic (SHL, \~30%) and nonsyndromic hearing loss (NSHL) ([@b2-mmr-16-06-7915],[@b3-mmr-16-06-7915]). SHL has \>400 types of symptoms in the skin, outer ears, eyes and endocrine metabolism. The present study examined a Chinese patient originally suspected to have certain types of SHL. The proband exhibited deafness along with various additional symptoms, including dry loose skin, tooth decay and hypotonia. These phenotypes partially conform to the symptoms of some diseases and syndromes, such as Hutchinson-Gilford progeria syndrome (HGPS) and congenital ectodermal dysplasia syndrome ([@b4-mmr-16-06-7915]--[@b7-mmr-16-06-7915]). HGPS is a rare syndrome characterized by slow growth, prominent eyes, protruding ears, a small chin, hair loss, ageing skin and loss of subcutaneous fat tissue. ([@b8-mmr-16-06-7915],[@b9-mmr-16-06-7915]) Generally, patients were born normal; however, ageing occurs rapidly, leading to alterations in various organs ([@b10-mmr-16-06-7915]). Some of the proband\'s symptoms also fall within those of ectodermal dysplasia syndrome (skin and tooth abnormality), whereas other diseases are also possible due to the multiple symptoms of the patient, such as hypogonadism. Genetically, HGPS occurs due to an autosomal dominant inheritance of a mutant lamin A/C (*LMNA*) gene ([@b11-mmr-16-06-7915]). Ectodermal dysplasia syndrome is attributed to copy number variations (CNVs) or mutations in ectodysplasin A (*EDA*) gene family members, including *EDA*, EDA receptor (*EDAR*) and EDAR-associated death domain. ([@b12-mmr-16-06-7915],[@b13-mmr-16-06-7915]) Therefore, genetic screening is of the utmost importance for diagnosis and treatment.

Given the possibility of HGPS and ectodermal dysplasia syndromes for the patient, sequencing of *LMNA* exons was performed, followed by CNV examination of *EDA* gene family members; however, no pathogenic clues were identified. Subsequently, 438 deafness-associated genes were sequenced, in order to identify if these mutations in these genes are associated with the patient\'s phenotypes. Whole-genome sequencing (WGS) was performed in order to identify potential pathogenic genes that may account for the symptoms observed. The obtained gene list with CNVs or single nucleotide variations (SNVs) was compared with the Human/Mouse Disease Connection database, other SNV-related databases and previous studies in order to identify potential candidate genes. Multiple genes were selected for further analysis.

Case report
===========

### Patient, ethics, consent and permission

Clinical information about the patient, aged 4, male, and the parents was collected in June 2014, followed by a systemic health check up, under signed informed consent forms to participate and publish the data in accordance with the Ethics Committee of the Chinese PLA General Hospital (Beijing, China). Peripheral blood (5 ml) was collected for genomic DNA (gDNA) isolation.

### Sequencing of the HGPS-associated LMNA gene

Primers were based on the NCBI reference sequence of *LMNA* (Genbank, NM_001282625) and were designed by Shanghai Genesky Biotech Co., Ltd. (Shanghai, China) to amplify exons with \~50 bp of flanking introns. Primer sequences are presented in [Table I](#tI-mmr-16-06-7915){ref-type="table"}. Polymerase chain reaction (PCR) products were purified for sequencing. PCR was performed by Shanghai Genesky Biotech Co., Ltd.

### Multiplex ligation-dependent probe amplification (MLPA) for EDA testing

MLPA was used for genetic testing of *EDA* using P183 kit according to the manufacturer\'s instructions (MRC-Holland, Amsterdam, Netherlands). DNA was denatured and hybridized with SALSA probe mix, followed by ligation and polymerase chain reaction amplification. Capillary electrophoresis was performed to generate fragment length and peak area using Genemapper software, version 3.0 (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Copy number ratio was denoted as peak area ratio of patient vs. references. A ratio between 0.7 and 1.3 indicated a normal individual, whereas the subject may be diagnosed with ectodermal dysplasia syndrome when the value falls between 1.7 and 2.3. Tests were repeated when the value was near the aforementioned boundaries.

### Sequencing of hearing impairment-associated genes

A total of 2 µg gDNA was sheared with NEBNext^®^ dsDNA Fragmentase (New England Biolabs, Inc., Ipswich, MA, USA) and end repaired with DNA End Repair Mix (Thermo Fisher Scientific, Inc.), followed by 3′-end adenylation (A-tailing kit; Generay Biotech Co., Ltd., Shanghai, China) and adaptor ligation (NEBNext^®^ Multiplex Oligos for Illumina^®^; New England BioLabs, Inc.) according to the respective manufacturer\'s instructions. PCR was performed with a primer cocktail using NEBNext^®^ Ultra™ II DNA Library Prep kit (New England BioLabs, Inc.), followed by purification. The thermocycling conditions were as follows: 98°C for 30 sec, 10 cycles of 98°C for 10 sec, 60°C for 30 sec and 72°C for 30 sec, followed by 72°C for 5 min. Subsequently, the library was pooled, hybridized and purified prior to another round of PCR amplification with the same thermocycling conditions as the ones stated above. Finally, samples were mounted on the Illumina HiSeq 2000 loading unit for sequencing.

### WGS procedure

WGS was performed using Illumina TruSeq Nano DNA HT Sample prep kit (Illumina, Inc., San Diego, CA, USA) and HiSeq X system (Illumina, Inc.), according to the manufacturer\'s protocol. For CNV analysis, sequences of 6 unrelated individuals were used as references. For SNV analysis, the criteria for gene selection were as follows: i) Existing mutations in HGMD; ii) conservation analysis; iii) frequency \<0.001 in 1,000 genomes or \<0.01 in its own genome; iv) frequency in ESP6500 \<0.01; v) single nucleotide polymorphism (SNP) calling quality not L (L meaning that the SNP cannot be called by either the GAKT or varscan programs), and the ratio of genotyping quality L \<50%; vi) homology is 1; and vii) zero occurrence in the Genesky database. SNP calling was performed using Genome Analysis Toolkit (version 3.7, Broad Institute; [software.broadinstitute.org/gatk](software.broadinstitute.org/gatk)) and VarScan (version 2.4.0; Genome Institute at Washington University; [genome.wustl.edu](genome.wustl.edu)). An SNP was labeled as 'H' if it was identified by both programs, whereas the quality was 'M' when it was detected by only one. The quality was further downgraded if there were short tandem repeats, indel or homologous sequences flanking the SNP. SNPs labeled as 'H' were selected in priority. The overall quality of SNP genotyping was 'L' or 'M'; therefore, if one sample was graded as 'L' or 'M' those graded as 'L' were selected. Genes with sorting intolerant from tolerant (SIFT) values \<0.05 were selected, as SIFT values indicate the impact of the mutation on protein functions. Additionally, sites with mutation taster scores have a higher probability of mutation. The original gene list was narrowed down according to the aforementioned criteria and genes associated with hearing impairment and HGPS were selected as priority. The list of genes carrying CNV or SNV was matched with the patient\'s symptoms, including progeria, either in the gene list or the Human-Mouse Disease Connection database ([www.informatics.jax.org/mgihome/homepages/humanDisease.shtml](www.informatics.jax.org/mgihome/homepages/humanDisease.shtml)). Genes of interest were selected for further analysis. An extensive search in existing literature was performed for the refined genes, in order to identify whether the detected mutations in the current patient had been reported to be the pathogenic cause of the phenotypes observed.

### Clinical check up of the family

The patient exhibited ageing skin loosening following birth, with limited skin elasticity and subcutaneous fat storage. He exhibited progeroid symptoms without age pigment deposition. Facial skin loosening was moderate; however, there was abnormal development in hair and teeth, with evident tooth decay. The patient had slow reaction to external forces and low muscle tension; however, no abnormality in eyesight, intelligence and overall skeletal development (no bone integration or bone loss) was observed. Additionally, no obvious abnormalities were detected in the nervous system check up. However, the development of the gonads was limited ([Fig. 1](#f1-mmr-16-06-7915){ref-type="fig"}).

The patient was not treated after birth. At age 1, the child was diagnosed with severe deafness. No abnormality was observed in skull/temporal bone computed tomography and skull/internal auditory canal magnetic resonance imaging scan prior to artificial cochlea implantation. The patient exhibited high aminotransferase levels; however, no chromosomal abnormality was identified. Following artificial cochlea implantation in 2013, hearing and skin resilience improved. His parents and sister were also examined and were determined to be in healthy condition. The patient was initially suspected to be deaf and have HGPS; therefore, genetic screening was used for diagnosis.

### LMNA gene mutation

No mutation was identified in the exons of the HGPS-associated gene *LMNA*. Exon sequencing of *LMNA* for the patient and his parents revealed no mutation of *LMNA* in the family.

### MLPA analysis excluded EDA syndrome

*EDA* peaks for the patient and reference samples are presented in the MLPA histogram of [Fig. 2](#f2-mmr-16-06-7915){ref-type="fig"} along with their ratios. Copy number ratios were \~1, suggesting no change in copy number. Therefore, ectodermal dysplasia syndrome due to dysfunction of EDA was excluded for this patient.

### Mutations of deafness-associated genes

Mono-allelic heterozygous mutations were identified in some genes, including coenzyme Q6 monooxygenase, *FGFR3*, melanogenesis associated transcription factor (*MITF*), otoferlin, DNA polymerase γ catalytic subunit (*POLG*) and usherin (*USH2A*). Mutation of these genes may contribute to other unrelated symptoms. For instance, a *POLG* mutation may lead to a mitochondrial DNA depletion syndrome, which is characterized by tubulopathy, seizures, respiratory distress, diarrhea and lactic acidosis, which were inconsistent with the majority of the phenotypes observed in the proband. Mutations in some of these genes were also revealed in WGS, and therefore will be discussed further in the following section.

### WGS revealed multiple genes that may account for specific symptoms

WGS identified CNV and SNV. From the CNV analysis, 2,653 genes were determined to have half or less copy numbers. Conversely, the remaining 720 genes had copy numbers \~2. For the SNV analysis, WGS confirmed the mutations of the aforementioned deafness-associated gene sequencing. Additionally, a full list of genes with autosomal dominant and recessive inheritance patterns were identified.

The genes of interest were identified by searching the lists against the symptoms. Briefly, their mutations were checked in the literature to see what symptoms they may cause. They were categorized according to the phenotypes of the patient in [Table II](#tII-mmr-16-06-7915){ref-type="table"}. Some of these genes or their SNVs have been well-characterized and have been identified to be responsible for various diseases. For instance, *USH2A* and *CDH23* were determined to be involved in the pathogenesis of Usher syndrome ([@b14-mmr-16-06-7915],[@b15-mmr-16-06-7915]). However, none of the identified genes were capable of simultaneously explaining the majority of the symptoms present in the proband, suggesting that the disease may not be attributed to a monogene and multiple genetic lesions may cooperatively contribute to the presentations in the patient. Additionally, the exact SNVs in a number of the listed genes were never reported to be pathogenic in any of the literature, let alone the symptoms presented by the proband in our study. In some cases, the diseases associated with the genes were reported to present major symptoms that were not observed in the present case, such as the Donnai-Barrow syndrome which occurs due to *LRP2* mutation ([@b16-mmr-16-06-7915]). Therefore, the majority of the listed genes were filtered out and only SNVs in the *LMNA*, DNA polymerase δ 1, catalytic subunit (*POLD1*), crystallin mu (*CRYM*), RAB3 GTPase activating protein catalytic subunit 1 (*RAB3GAP1*) and Wnt family member 10A (*WNT10A*) genes were further discussed.

Discussion
==========

The proband exhibited multiple symptoms, including deafness, ageing and hypogonadism, which partially conform to the symptoms of HGPS and ectodermal dysplasia syndrome. HGPS is a rare hereditary disease which occurs due to autosomal dominant inheritance of mutant *LMNA*, the product of which promotes nuclear membrane deformation and reduces cellular lifespan ([@b17-mmr-16-06-7915]). Previous studies identified the following pathogenic mutations c.1824C\>T (p.Gly608Gly), c.1822G\>A (p.Gly608Ser), c.1821G\>A (p.Val607Val), c.1968+1G\>A ([@b18-mmr-16-06-7915],[@b19-mmr-16-06-7915]). Pathogenic mutations such as c.1824C\>T (p.Gly608Gly), do not alter the amino acid sequence; however, they activate a hidden cleavage site, which leads to the deletion of 50 amino acids in the resulting protein ([@b20-mmr-16-06-7915],[@b21-mmr-16-06-7915]). The present study also identified a synonymous SNV of c.1698C\>T, p.His566His (chr1:156107534, NM_001282626, rs4641) at the splice region. However, the allele frequency carrying this SNV is 26.55% according to ExAC Browser database; therefore, excluding the possibility of rare HGPS in the current patient.

Another gene of interest is *POLD1*, the defects of which (serine 605 loss or R507C substitution at exon 13) lead to loss of δ DNA polymerase activity and impairment of proof-reading exonuclease activity ([@b22-mmr-16-06-7915]--[@b24-mmr-16-06-7915]). This may lead to mandibular dysplasia with deafness and progeroid features (MDP), which is characterized by lipodystrophy, deafness, a small lower jaw, low testosterone levels, claw toes, joint stiffness and hypogonadism ([@b25-mmr-16-06-7915]). However, the nonsynonymous SNV detected in this patient is 1932C\>G at exon 16 in *POLD1* gene (rs80214209), which has been reported in \>90 individuals, particularly in East Asia according to ExAC Browser database. Given that the MDP syndrome is an extremely rare syndrome with only 5 reported cases exhibiting a different *POLD1* SNV ([@b24-mmr-16-06-7915]), it is unlikely that the SNV in *POLD1* observed in the present study leads to MDP syndrome. The molecular pathogenesis that results in progeria-like features remains to be further elucidated.

Ectodermal dysplasia syndrome occurs partially due to mutations and CNVs in *EDAs* ([@b12-mmr-16-06-7915],[@b13-mmr-16-06-7915]). The protein products of these genes participate in signaling pathways that regulate interactions between the ectoderm and mesoderm, critical for the formation of skin, hair, teeth and sweat glands. However, no CNV or SNV were detected in the *EDAs*; therefore, this case is unlikely to be *EDA*-caused ectodermal dysplasia. However, it is possible that ectodermal dysplasia may be induced by other gene mutations; for example, c.637G\>A, p.G213S of *WNT10A*.

Deafness may be induced by mutations in multiple genes, such as *USH2A*, *CDH23* as listed in [Table II](#tII-mmr-16-06-7915){ref-type="table"}. A dominant splicing alteration (rs189371585) in the *CRYM* gene was identified as a candidate etiological gene for deafness, with an allele frequency of 0.46% in the 1,000 genome phase 1 population according to the SNP database (dbSNP). Alterations of *CRYM* (X315Y and K314T) have been determined to lead to autosomal dominant NSHL ([@b26-mmr-16-06-7915]--[@b28-mmr-16-06-7915]). However, the pathogenic changes previously observed occurred due to an amino acid substitution ([@b26-mmr-16-06-7915]), whereas the present case exhibited alterations in splicing. At present, no existing literature is available to link this alteration to any pathogenic consequences. Further functional analysis is required to confirm the biological effects of this splicing mutation.

Mutations in several genes may give rise to hypogonadism, including *MITF* and KiSS-1 metastasis-suppressor. Additionally, diseases associated with mutations in *RAB3GAP1* include Warburg Micro syndrome and Martsolf syndrome ([@b29-mmr-16-06-7915]--[@b33-mmr-16-06-7915]). Leiden open source variation database archived nonsense mutations at c.1174 that led to the production of truncated protein terminating at p.R392 and contributed to Warburg Micro Syndrome. The novel SNV of c.1175G\>A in *RAB3GAP1* identified in the present study led to a p.R392Q amino acid substitution. Albeit at the same position, no previous studies have reported the pathogenic role of the SNV (p.R392Q) detected in the present study in Warburg Micro syndrome. Additionally, Warburg Micro syndrome is an autosomal recessive disease; however, only the symptom of hypogonadism was consistent with the present case. Therefore, the function of the *RAB3GAP1* mutation in the current proband remains unclear.

The present study was unable to identify definitive gene lesions that may account for the aforementioned symptoms. However, an SNV in *WNT10A* was confirmed to be etiological of tooth agenesis and ectodermal dysplasia. *WNT10A* produces a protein that triggers the Wnt pathway, which is important for development and oncogenesis. Mutations in the *WNT10A* gene may lead to aberrant development, such as odonto-onycho-dermal dysplasia, featured by tooth agenesis and ectodermal dysplasia ([@b34-mmr-16-06-7915]--[@b40-mmr-16-06-7915]). Previous studies also demonstrated some overlapping functions of *WNT10A* with *EDAs* in inducing hypodontia and ectodermal dysplasia ([@b41-mmr-16-06-7915]--[@b43-mmr-16-06-7915]). Ectodermal dysplasia syndrome exhibits a broad range of symptoms, including but not confined to abnormality of hair growth, absence or malformation of some or all teeth, inability to perspire, impairment or loss of hearing or vision and irregular skin pigmentation. The case presented here conforms to these symptoms in terms of tooth agenesis and hearing loss. Using WGS, a non-synonymous SNV of c.637G\>A, p.G213S in *WNT10A* was detected. This mutation has been previously reported to be the etiological variant leading to tooth agenesis ([@b35-mmr-16-06-7915],[@b43-mmr-16-06-7915]). In the absence of alterations in EDA members, this variant may also give rise to ectodermal dysplasia ([@b34-mmr-16-06-7915]). Therefore, the gene screening performed in the present study identified the function of the *WNT10A* mutation p.G213S in the induction of tooth agenesis, skin abnormalities and hearing loss.

In conclusion, although further investigation is required to confirm the pathogenic role of some of the SNVs identified in inducing the phenotypes observed, the present study provides an example of the use of genetic screening tools for the diagnosis of a patient with putative syndromic deafness. However, the symptoms were ultimately determined to be attributed to multiple genetic lesions as opposed to a single gene, the present study determined that a *WNT10A* mutation contributes to the tooth agenesis and ectodermal dysplasia observed in the patient. Additionally, a novel SNV of *CRYM* and an existing SNV of *RAB3GAP1* were identified, their function in inducing deafness and hypogonadism require further exploration. The present study provided an example of the use gene screening tools in the diagnosis of a patient with complicated symptoms.
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![Systemic check up of the patients revealed (A and B) ageing symptoms in the skin, (C) undescended testes and (D) falling off of teeth.](MMR-16-06-7915-g00){#f1-mmr-16-06-7915}

![Multiplex ligation-dependent probe amplification analysis of ectodermal dysplasia-associated genes. DNA was denatured and hybridized with SALSA probe mix, followed by ligation and polymerase chain reaction amplification. Capillary electrophoresis was performed to generate fragment length and peak area using GeneMapper version 3.0 software. Copy number ratio is denoted as the ratio of peak area of patient vs. peak area of references. Blue color peaks represent the patient sample, whereas the red color peaks were reference.](MMR-16-06-7915-g01){#f2-mmr-16-06-7915}

###### 

Amplification primers of *LMNA* gene.

  Exons   Forward (5′-3′)        Reverse (5′-3′)          Length (bp)
  ------- ---------------------- ------------------------ -------------
  1       CCAGGAGCAAGCCGAGAG     ACAATTCCCCTTGACACTGC     990
  2       GGATGCCCTCTCCTGGTAAT   GGCTCTGAAATCAGGTGACAG    700
  3       CCTGGACCTGTTTCCACAT    TAACCTGGGAGCTGAGTGCT     680
  4       CCTAGTGGACAGGGAGTTGG   CCTGAGTTGGGCATCACTG      640
  5       TAGCAGTGATGCCCAACTCA   GCCATCTGACTCCACATCCT     640
  6,7     CTCTGGGGAAGCTCTGATTG   TCTCACAGCCAAAGAGTCCA     1,130
  8,9     CAGGGGTGTGTGTAGATGGA   GTTTGCCTACTGGGTGGAGA     860
  10      AAGTTGCAGGTGGTCACTGG   GAAAGTTCCCACTCCCTTCC     600
  11      GCACAGAACCACACCTTCCT   GGTGGGCTGTCTAGGACTCA     800
  12      CATCCTGCCCCTCTTGTCT    TTTTGCTTGTGTTTTTCCTTCA   520

###### 

Patient phenotypes, associated genes, mutations and diseases attributed to alterations in the genes.

  A, Aging/progeria                                                                                                      
  ---------------------- -------------------------------------------------------------------------------- -------------- -----------------------------------------
  LRP1                   NA                                                                               NM_002332      c.12161A\>T:p.Y4054F
  *EDNRA*                Mandibulofacial dysostosis with alopecia                                         NM_001166055   c.503T\>C:p.L168P
  *POLG*                 Mitochondrial DNA depletion syndrome                                             NM_001126131   c.1840T\>C:p.Y614H
  SREBF1                 NA                                                                               NM_001005291   c.547G\>A:p.A183T
  CANX                   NA                                                                               NM_001024649   c.418C\>A:p.L140M
  BAK1                   NA                                                                               NM_001188      Splicing
  *POLD1*                Mandibular hypoplasia, deafness, progeroid features and lipodystrophy syndrome   NM_001256849   c.1932C\>G:p.D644E
  *LRP2*                 Donnai-barrow syndrome                                                           NM_004525      CNV ratio=0.54
  *CISD2*                Wolfram syndrome                                                                 NM_001008388   CNV ratio=2.03
  VCAM1                  NA                                                                               NM_001078      CNV ratio=0.52
  CASP7                  NA                                                                               NM_033338      CNV ratio=0.52
  SLC18A2                NA                                                                               NM_003054      CNV ratio=0.60
  IL15                   NA                                                                               NM_000585      CNV ratio=0.60
  ADH5                   NA                                                                               NM_000671      CNV ratio=0.58
  SLC6A3                 NA                                                                               NM_001044      CNV ratio=0.53
  HMGCR                  NA                                                                               NM_000859      CNV ratio=0.58
  DLD                    NA                                                                               NM_000108      CNV ratio=0.58
  DDC                    NA                                                                               NM_001082971   CNV ratio=0.59
  MSRA                   NA                                                                               NM_001135670   CNV ratio=1.84
  GSN                    NA                                                                               NM_000177      CNV ratio=0.52
  MLIP                   NA                                                                               NM_001281746   CNV ratio=0.54
                                                                                                                         
  B, Deafness                                                                                                            
                                                                                                                         
  Gene name              Disease                                                                          RefSeq mRNA    CNV/SNV
                                                                                                                         
  USH2A                  Usher syndrome II                                                                NM_206933      c.5608C\>T:p.R1870W c.9340C\>T:p.P3114S
  CDH23                  Usher syndrome                                                                   NM_022124      c.5418C\>G:p.D1806E
  CRYM                                                                                                    NM_001888.4    Splicing
  COQ6                   Nephrotic syndrome                                                               NM_182476      c.186C\>A:p.D62E
  FBXO2                  NA                                                                               NM_012168      Splicing
  STRC                   NA                                                                               NM_153700      c.179T\>C:p.F60S
  VPS13B                 Cohen syndrome                                                                   NM_152564      c.11884C\>G:p.P3962A
  OTOF                                                                                                    NM_194248      c.2123G\>A:p.R708Q
  *CISD2*                Wolfram syndrome                                                                                CNV ratio=2.03
  *LRP2*                 Donnai-barrow syndrome                                                           NM_004525      CNV ratio=0.54
  *SMCHD1*               Facioscapulohumeal muscular dystrophy                                            NM_015295      c.4071T\>G:p.I1357M
  *POLD1*                Mandibular hypoplasia, deafness, Progeroid                                       NM_001256849   c.1932C\>G:p.D644E
                         features, and lipodystrophy syndrome                                             NM_001256849   c.1932C\>G:p.D644E
  *POLG*                 Mitochondrial DNA depletion syndrome                                             NM_001126131   c.1840T\>C:p.Y614H
                                                                                                                         
  C, Hypogonadism                                                                                                        
                                                                                                                         
  Gene name              Disease                                                                          RefSeq mRNA    CNV/SNV
                                                                                                                         
  RAB3GAP                Warburg syndrome, martsolf syndrome                                              NM_012233      c.1175G\>A:p.R392Q
  *MITF*                 Warburg syndrome                                                                 NM_198158      c.1235C\>T:p.T412I
  *MAGEL2*               Prader-willi syndrome                                                            NM_019066      c.1425_1445del:p.475_482del
  KISS1                                                                                                   NM_002256      c.417delA:p.X139W
  NRP2                                                                                                    NM_201266      c.1333A\>C:p.I445L
  *CISD2*                Wolfram syndrome                                                                 NM_001008388   CNV ratio=2.031485778
  *POLD1*                Mandibular hypoplasia, deafness, progeroid features and lipodystrophy syndrome   NM_001256849   c.1932C\>G:p.D644E
  Fras1                  Fraser syndrome                                                                  NM_025074      CNV ratio=0.59
                                                                                                          NM_025074      c.9356A\>G:p.N3119S
                                                                                                                         
  D, Hypotonia                                                                                                           
                                                                                                                         
  Gene name              Disease                                                                          RefSeq mRNA    CNV/SNV
                                                                                                                         
  *MAGEL2*               Prader-willi syndrome                                                            NM_019066      c.1425_1445del:p.475_482del
  *POLG*                 Mitochondrial DNA depletion syndrome                                             NM_001126131   c.1840T\>C:p.Y614H
  *SMCHD1*               Facioscapulohumeral muscular dystrophy                                           NM_015295      c.4071T\>G:p.I1357M
                                                                                                                         
  E, Tooth development                                                                                                   
                                                                                                                         
  Gene name              Disease                                                                          RefSeq mRNA    CNV/SNV
                                                                                                                         
  *EDNRA*                Mandibulofacial dysostosis with alopecia                                         NM_001166055   c.503T\>C:p.L168P
  *POLD1*                Mandibular hypoplasia, deafness, progeroid features and lipodystrophy syndrome   NM_001256849   c.1932C\>G:p.D644E
  *WNT10A*               Odonto-onycho-dermal dysplasia                                                   NM_025216      c.637G\>A:p.G213S

Genes in italics were associated with \>1 symptom. NA, no definite disease is reported to be linked to the gene mutation.

[^1]: Contributed equally
